RALEIGH – Aer Therapeutics,a startup focusing on lung disease and what it calls “a novel inhaled approach” for treatment, has closed on $15.8 million in funding from 23 investors. But the company wants a lot more.
In an SEC filing, Aer says its goal is to raise $36.8 million in all.
“We are focused on treating respiratory diseases with significant unmet needs, such as COPD, cystic fibrosis and asthma,” the company says at its website.
Jim Shaffer, the CEO, signed the filing. He recently joined the company.
“Jim is a seasoned biotech executive with over 25 years of experience working for emerging biotechnology and large pharma companies,” the company said in an announcement at LinkedIn.
Among his previous jobs was an eight-year tenure at GSK.
Jim Shaffer (AER Therapeutics photo)
